This “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CAR T-Cell Therapy for Multiple Myeloma Understanding
Multiple Myeloma also known as Kahler's disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn't cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
"CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.
This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy for the treatment of patients with multiple myeloma. The design comprises a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies. CAR-T cells are an innovative approach to eradicating cancer cells by harnessing the power of a patient's own immune system. BCMA is a protein that is highly expressed on myeloma cells. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech to develop and commercialise cilta-cel. The biologics license application for ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma has been accepted and granted priority review by the FDA. The FDA has set a target action date of November 29, 2021.
CT103A is a fully-human B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy co-developed by IASO Bio and Innovent and it is currently under the pivotal Phase III clinical trial. In February 2021, CT103A was granted the Breakthrough Therapy Designation (BTD) by China regulatory authority National Medical Production Administration (NMPA) for the treatment of relapsed/refractory multiple myeloma.
P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen, or BCMA. The company is currently evaluating P-BCMA-101 in a potentially registrational Phase II clinical trial and expanded Phase I clinical trial for the treatment of patients with relapsed/refractory multiple myeloma in the outpatient setting.
This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 30+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the most advanced stage, i.e. Preregistration include, Janssen Research and Development.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 3-5 business days.
Geography Covered
- Global coverage
CAR T-Cell Therapy for Multiple Myeloma Understanding
CAR T-Cell Therapy for Multiple Myeloma: Overview
Multiple Myeloma also known as Kahler's disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn't cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
"CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Chapters
This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs
Ciltacabtagene Autoleucel: Janssen Research and Development
Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy for the treatment of patients with multiple myeloma. The design comprises a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies. CAR-T cells are an innovative approach to eradicating cancer cells by harnessing the power of a patient's own immune system. BCMA is a protein that is highly expressed on myeloma cells. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech to develop and commercialise cilta-cel. The biologics license application for ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma has been accepted and granted priority review by the FDA. The FDA has set a target action date of November 29, 2021.
CT103A: innovent Biologics
CT103A is a fully-human B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy co-developed by IASO Bio and Innovent and it is currently under the pivotal Phase III clinical trial. In February 2021, CT103A was granted the Breakthrough Therapy Designation (BTD) by China regulatory authority National Medical Production Administration (NMPA) for the treatment of relapsed/refractory multiple myeloma.
- Descartes-11:Cartesian Therapeutics
P-BCMA-101: Poseida Therapeutics
P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen, or BCMA. The company is currently evaluating P-BCMA-101 in a potentially registrational Phase II clinical trial and expanded Phase I clinical trial for the treatment of patients with relapsed/refractory multiple myeloma in the outpatient setting.
CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in CAR T-Cell Therapy for Multiple Myeloma
There are approx. 30+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the most advanced stage, i.e. Preregistration include, Janssen Research and Development.
Phases
This report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CAR T-Cell Therapy for Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.
CAR T-Cell Therapy for Multiple Myeloma Report Insights
- CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
CAR T-Cell Therapy for Multiple Myeloma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR T-Cell Therapy for Multiple Myeloma drugs?
- How many CAR T-Cell Therapy for Multiple Myeloma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
- What are the key designations that have been granted to the emerging drugs?
This product will be delivered within 3-5 business days.
Table of Contents
IntroductionExecutive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
- Comparative Analysis
Ciltacabtagene Autoleucel: Janssen Research and Development
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Descartes-11:Cartesian Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I/II)
- Comparative Analysis
BCMA CAR-T cells: Chongqing Precision Biotech
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
CAR T-Cell Therapy for Multiple Myeloma Key Companies
AppendixList of Tables
Table 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Janssen Research & Development, LLC
- Innovent Biologics
- Cartesian Therapeutics
- Nanjing Legend Biotech Co.
- Allogene Therapeutics
- Chongqing Precision Biotech Co., Ltd
- AGC Biologics S.p.A
- Carbiogene Therapeutics
- Gilead Sciences
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Juno Therapeutics
- Cellular Biomedicine Group
- Poseida Therapeutics
- Carsgen Therapeutics
- Caribou Biosciences
- Elpis Biopharmaceuticals
- Hemalogix
- JW Therapeutics
- CRISPR Therapeutics
- Allife Medical Science and Technology
- Yake Biotechnology
- Sorrento therapeutics
- Celyad Oncology
